Key result
A meta-analysis reported a threefold increased risk for malignancy (OR 3.3) with anti-TNF monoclonal antibody therapy in rheumatoid arthritis, though this commentary cautions that the control arm malignancy rate was unexpectedly low.
Why the study?
Does anti-tumour necrosis factor monoclonal antibody therapy increase the risk of malignancy and serious infection in rheumatoid arthritis patients?
Population
Rheumatoid arthritis patients
Design
Editorial
Authors
Loading...
This commentary urges caution in interpreting a meta-analysis that suggested an increased risk of malignancy and serious infection with anti-TNF therapy in rheumatoid arthritis, citing methodological issues.
Does anti-tumour necrosis factor monoclonal antibody therapy increase the risk of malignancy and serious infection in rheumatoid arthritis patients?
Odds Ratio: 3.3 (95% CI 1.2–9.1)
This commentary urges caution in interpreting a meta-analysis that suggested an increased risk of malignancy and serious infection with anti-TNF therapy in rheumatoid arthritis, citing methodological issues.
Dixon et al. (2006) conducted an editorial in Rheumatoid arthritis. Anti-TNF monoclonal antibodies (infliximab or adalimumab) vs. Standard treatment was evaluated on Malignancy (OR 3.3, 95% CI 1.2-9.1). A meta-analysis reported a threefold increased risk for malignancy (OR 3.3) with anti-TNF monoclonal antibody therapy in rheumatoid arthritis, though this commentary cautions that the control arm malignancy rate was unexpectedly low.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: